Description:
Mirabegron (formerly YM-178, trade name Myrbetriq) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012. Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity
- Molecular Weight:396.51
- Boiling Point:690.0±55.0 °C at 760 mmHg
- Melting Point:138-145°C
- Purity:0.99
Molecular Formula:
C21H24N4O2S
Canonical SMILES:
C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
InChI:
InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
InChIKey:
PBAPPPCECJKMCM-IBGZPJMESA-N
Appearance:
White to Off-White Solid
Application:
Adrenergic beta-3 Receptor Agonists
Storage: Store in a tightly closed container , in a cool and dry place.
Synonyms:
YM-178; YM 178; YM178 More details are to be found
here
details
details
details